$RLMD's NDV-01 showed 76% 12-mo CR in NMIBC, 80% in BCG-unresponsive; no ≥Grade 3 AEs. $160M PIPE with top HC investors. Phase 3 to start mid-2026.
www.biopharmcatalyst.com/news/2026/re...
$RLMD's NDV-01 showed 76% 12-mo CR in NMIBC, 80% in BCG-unresponsive; no ≥Grade 3 AEs. $160M PIPE with top HC investors. Phase 3 to start mid-2026.
www.biopharmcatalyst.com/news/2026/re...
BioPharmCatalyst's weekly watchlist features key biotech stocks and catalysts to watch this quarter. Stay updated with daily insights and news. www.biopharmcatalyst.com/news/2026/bi...
06.03.2026 21:15 — 👍 0 🔁 0 💬 0 📌 0
$CLDI plans public offering of stock/warrants; underwriters get 45-day option for extra shares. Proceeds for working capital.
www.biopharmcatalyst.com/news/2026/ca...
$PEPG ends 2025 with $148.5M cash, funds into 2H27. Key DM1 Phase 2 data expected Q1 & 2H 2026. FDA hold on FREEDOM2, not due to safety.
www.biopharmcatalyst.com/news/2026/pe...
$CANF’s namodenoson met safety goals in Phase IIa pancreatic cancer trial; well-tolerated, survival data pending. Further clinical development supported.
www.biopharmcatalyst.com/news/2026/ca...
$MAIA jumps on $30M equity raise at $1.50/share, boosting funds but causing near-term dilution. Healthcare investors led; no warrants. $ITRM $HROW $CERS $IRON $ATRA $IDYA $ESLA $ENSC $LYRA
www.biopharmcatalyst.com/news/2026/ma...
$AARD paused Phase 3 HERO trial for ARD-101 in PWS due to cardiac concerns at high doses, delaying topline data and creating regulatory uncertainty.
www.biopharmcatalyst.com/news/2026/aa...
BioPharmCatalyst Watchlist: Key small/mid-cap PDUFA catalysts this week. Top tickers: RCKT, RYTM, ALDX, GSK, BMY, LNTH. Full list & news: biopharmcatalyst.com www.biopharmcatalyst.com/news/2026/bi...
27.02.2026 21:15 — 👍 0 🔁 0 💬 0 📌 0
$ENSC begins review of strategic options to boost shareholder value; may consider partnerships, asset sales, or other deals. No set timeline or further updates planned.
www.biopharmcatalyst.com/news/2026/en...
$CURX finished a GMP batch of Phyto-N, clearing the way for GLP studies and a planned 4Q26 IND in ulcerative colitis—key step toward first-in-human trials.
www.biopharmcatalyst.com/news/2026/cu...
$IXHL announces 1-for-30 reverse split effective Feb 26, 2026, aiming to boost share price and maintain Nasdaq listing.
www.biopharmcatalyst.com/news/2026/ge...
$VIR partners with Astellas on prostate cancer therapy, reports positive Phase 1 data, ends 2025 with $781.6M cash.
www.biopharmcatalyst.com/news/2026/ma...
$GILD to acquire $ACLX for $115/share plus $5 CVR, securing BCMA CAR-T. Deal valued at $7.8B. FDA BLA accepted; PDUFA Dec 23, 2026. $ACLX $GILD #PremarketMovers
www.biopharmcatalyst.com/news/2026/gi...
Biopharma Watchlist: Key Phase 1/2 catalysts this quarter. Highlights: RGNX, CYBN, PEPG, BMEA, FGEN & more. Full list: biopharmcatalyst.com www.biopharmcatalyst.com/news/2026/bi...
20.02.2026 21:15 — 👍 0 🔁 0 💬 0 📌 0
$MGRX's $99/month TRT program drives 336% sales growth, 54% lower acquisition costs since Dec launch, boosting its telehealth expansion.
www.biopharmcatalyst.com/news/2026/ma...
$TRAW: Phase 2 shows ratutrelvir rivals PAXLOVID with fewer side effects, no rebound. Tivoxavir shows promise as monthly flu prevention; US study on hold for FDA feedback.
www.biopharmcatalyst.com/news/2026/pm...
$TCMD Q4 rev +21% to $103.6M, adj. EBITDA $22.9M. FY rev $329.5M, EBITDA $44.8M. Repaid $26.3M debt, $26.5M buybacks, cash $83.4M. $TCMD $SPRB $APRE $RXRX $ADVB $KLRS $MNDR $BAYRY $SHPH
www.biopharmcatalyst.com/news/2026/ta...
$CMPS: Phase 3 trials show strong results for COMP360 in depression, rapid & lasting effect, well-tolerated. NDA planned Q4 after FDA talks. $CMPS + others move pre-market.
www.biopharmcatalyst.com/news/2026/co...
Pre-market movers: $IMUX, $VTGN, $CHRS, $QNCX, $BIO, $OKYO, $JSPR, $BRTX, $ABP, $ARTL.
LINK
BioPharmCatalyst Weekly Watchlist: Top Phase 3 catalysts left this quarter. Key tickers: OCUL, BCRX, GOSS & more. Details: www.biopharmcatalyst.com/news/2026 www.biopharmcatalyst.com/news/2026/bi...
13.02.2026 21:15 — 👍 0 🔁 0 💬 0 📌 0
$IMUX issues warrants for up to 229M shares at $0.873, aiming to raise $200M. Warrants expire 30 days after Phase 3 data or Feb 2031. Supports commercial plans. $IMUX $VTGN $CHRS
www.biopharmcatalyst.com/news/2026/im...
$NVCR jumps after FDA OKs Optune Pax for advanced pancreatic cancer, first new treatment in decades. Phase 3 showed improved survival.
www.biopharmcatalyst.com/news/2026/no...
$UPB's Phase 2 asthma drug cut exacerbations by 56% & improved lung function. $UPB, $QNCX, $STIM, $ELAB among notable pre-market movers.
www.biopharmcatalyst.com/news/2026/up...
$EVMN up on positive Phase 2a EVO301 data in atopic dermatitis: 33% placebo-adjusted EASI at week 12, clean safety, moving to Phase 2b.
www.biopharmcatalyst.com/news/2026/ev...
$TNON projects Q4 revenue of $1.45M–$1.48M, reaffirming a strong 2025 outlook.
www.biopharmcatalyst.com/news/2026/te...
BioPharmCatalyst Weekly Watchlist: Key biotech catalysts for GOSS, RGNX, PVLA, KOD, ALDX & more in the next 6 months. Daily insights & news. Full list: biopharmcatalyst.com www.biopharmcatalyst.com/news/2026/bi...
06.02.2026 21:15 — 👍 0 🔁 0 💬 0 📌 0
$NVST Q4: Core sales +10.8%, adj. EBITDA +22% ($111M), EPS +58%. FY25: Sales +6.5%, EBITDA +26%. Returned $166M via buybacks. 2026 EPS guide: $1.35-$1.45, sales +2-4%.
www.biopharmcatalyst.com/news/2026/he...
$ALGN beats Q4 estimates with strong Invisalign demand. EPS $3.29, revenue $1.05B. Q1 guidance in line, though margin below. Needham: Hold, outlook "achievable." $ALGN #premarket
www.biopharmcatalyst.com/news/2026/al...
$ALGN beats earnings & revenue estimates on strong Invisalign demand; guides Q1 revenue $1.01-$1.03B, margin below consensus. Needham maintains Hold, outlook "fairly achievable."
www.biopharmcatalyst.com/news/2026/al...
